JP2015509972A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509972A5
JP2015509972A5 JP2014561514A JP2014561514A JP2015509972A5 JP 2015509972 A5 JP2015509972 A5 JP 2015509972A5 JP 2014561514 A JP2014561514 A JP 2014561514A JP 2014561514 A JP2014561514 A JP 2014561514A JP 2015509972 A5 JP2015509972 A5 JP 2015509972A5
Authority
JP
Japan
Prior art keywords
compound
formula
metal salt
lactose
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014561514A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015509972A (ja
JP6189874B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2013/050623 external-priority patent/WO2013136075A1/en
Publication of JP2015509972A publication Critical patent/JP2015509972A/ja
Publication of JP2015509972A5 publication Critical patent/JP2015509972A5/ja
Application granted granted Critical
Publication of JP6189874B2 publication Critical patent/JP6189874B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014561514A 2012-03-13 2013-03-13 新規製薬学的製剤 Expired - Fee Related JP6189874B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261610023P 2012-03-13 2012-03-13
US201261610012P 2012-03-13 2012-03-13
US61/610,012 2012-03-13
US61/610,023 2012-03-13
PCT/GB2013/050623 WO2013136075A1 (en) 2012-03-13 2013-03-13 Novel pharmaceutical formulations

Publications (3)

Publication Number Publication Date
JP2015509972A JP2015509972A (ja) 2015-04-02
JP2015509972A5 true JP2015509972A5 (enExample) 2016-04-14
JP6189874B2 JP6189874B2 (ja) 2017-08-30

Family

ID=49160309

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014561514A Expired - Fee Related JP6189874B2 (ja) 2012-03-13 2013-03-13 新規製薬学的製剤
JP2014561515A Pending JP2015509973A (ja) 2012-03-13 2013-03-13 結晶性pi3キナーゼ阻害剤
JP2017151378A Withdrawn JP2018008992A (ja) 2012-03-13 2017-08-04 結晶性pi3キナーゼ阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014561515A Pending JP2015509973A (ja) 2012-03-13 2013-03-13 結晶性pi3キナーゼ阻害剤
JP2017151378A Withdrawn JP2018008992A (ja) 2012-03-13 2017-08-04 結晶性pi3キナーゼ阻害剤

Country Status (35)

Country Link
US (3) US20150099768A1 (enExample)
EP (2) EP2825202B1 (enExample)
JP (3) JP6189874B2 (enExample)
KR (2) KR20140141596A (enExample)
CN (2) CN104302650B (enExample)
AU (2) AU2013234080B2 (enExample)
CA (2) CA2864643A1 (enExample)
CL (2) CL2014002385A1 (enExample)
CO (2) CO7061079A2 (enExample)
CR (2) CR20140417A (enExample)
CY (1) CY1118565T1 (enExample)
DK (1) DK2834244T3 (enExample)
EA (2) EA025465B1 (enExample)
EC (2) ECSP14018142A (enExample)
ES (2) ES2650791T3 (enExample)
GT (2) GT201400182A (enExample)
HR (1) HRP20161383T1 (enExample)
HU (1) HUE029420T2 (enExample)
IL (2) IL233883A0 (enExample)
IN (2) IN2014MN01998A (enExample)
LT (1) LT2834244T (enExample)
MX (2) MX355299B (enExample)
MY (1) MY171125A (enExample)
NI (2) NI201400100A (enExample)
NZ (2) NZ627963A (enExample)
PE (2) PE20142342A1 (enExample)
PH (2) PH12014501713A1 (enExample)
PL (1) PL2834244T3 (enExample)
PT (1) PT2834244T (enExample)
SG (2) SG11201404519UA (enExample)
SI (1) SI2834244T1 (enExample)
TW (2) TWI617561B (enExample)
UA (1) UA115544C2 (enExample)
WO (2) WO2013136075A1 (enExample)
ZA (2) ZA201407373B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
UA115544C2 (uk) 2012-03-13 2017-11-27 Респіверт Лімітед Спосіб підвищення стабільності до хімічного розкладання фармацевтичної композиції та застосування стабілізуючого агента у фармацевтичній коипозиції
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2889905A1 (en) 2012-11-08 2014-05-15 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor
TW201522341A (zh) 2013-03-15 2015-06-16 Respivert Ltd 化合物
US9227977B2 (en) 2013-03-15 2016-01-05 Respivert Ltd. Phosphoinositide 3-kinase inhibitors
UA121104C2 (uk) 2013-10-04 2020-04-10 Інфініті Фармасьютикалз, Інк. Гетероциклічні сполуки і їх застосування
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
NZ724368A (en) 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
JP6291601B2 (ja) 2014-07-04 2018-03-14 ルピン・リミテッド Pi3k阻害剤としてのキノリジノン誘導体
ES2701525T3 (es) 2014-07-09 2019-02-22 Arven Ilac Sanayi Ve Ticaret As Un procedimiento para la preparación de formulaciones para inhalación
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
SG10202010192YA (en) 2016-04-15 2020-11-27 Chia Tai Tianqing Pharmaceutical Group Co Ltd Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
WO1999028979A2 (en) 1997-12-02 1999-06-10 Alcatel Usa Sourcing, L.P. Digital phone system
NZ511527A (en) * 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
US6383790B1 (en) 1999-01-11 2002-05-07 Princeton University High affinity protein kinase inhibitors
ATE363892T1 (de) 1999-03-05 2007-06-15 Chiesi Farma Spa Verbesserte pulverformulierungen zur inhalation
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
EP1578898A2 (en) 2001-07-13 2005-09-28 Virtual Drug Development, Inc. Nad synthetase inhibitors and uses thereof
WO2003007955A2 (en) 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
AU2003301662A1 (en) 2002-10-21 2004-05-13 Bristol-Myers Squibb Company Quinazolinones and derivatives thereof as factor xa inhibitors
EP2385040A1 (en) 2003-03-14 2011-11-09 ONO Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
JP2007524605A (ja) 2003-04-03 2007-08-30 ピーディーエル バイオファーマ,インコーポレイティド インテグリンα5β1のインヒビターおよび組織顆粒化の制御のためのそれらの使用
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
GB0316341D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
EP1643973A1 (en) * 2003-07-11 2006-04-12 Glaxo Group Limited Pharmaceutical formulations comprising magnesium stearate
EP1661879A4 (en) 2003-08-04 2006-11-29 Ono Pharmaceutical Co A DIPHENYL ETHER COMPOUND, PROCESS FOR THE PRODUCTION AND USE THEREOF
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
WO2005016349A1 (en) 2003-08-14 2005-02-24 Icos Corporation Methods of inhibiting leukocyte accumulation
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
CA2552664A1 (en) 2004-01-08 2005-07-28 Michigan State University Methods for treating and preventing hypertension and hypertension-related disorders
WO2005112935A1 (en) 2004-05-13 2005-12-01 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
EP1761540B1 (en) 2004-05-13 2016-09-28 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
EP1755609A1 (en) 2004-05-25 2007-02-28 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
JP2008501707A (ja) 2004-06-04 2008-01-24 アイコス、コーポレーション マスト細胞障害を処置するための方法
AR050643A1 (es) 2004-09-13 2006-11-08 Ono Pharmaceutical Co Un derivado heterociclico que contiene nitrogeno y un farmaco que contiene el mismo como el ingrediente activo
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
WO2006089106A2 (en) 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
KR20120051760A (ko) 2006-04-04 2012-05-22 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
CN101448505A (zh) 2006-04-04 2009-06-03 加利福尼亚大学董事会 Pi3激酶拮抗剂
MX2008014910A (es) 2006-05-24 2009-01-23 Bayer Schering Pharma Ag Anticuerpos bloqueantes de la funcion de la integrina ?5?1 humanos y humanizados de gran afinidad con inmunogenicidad reducida.
CA2655720A1 (en) 2006-06-29 2008-01-10 Schering Corporation Substituted bicyclic and tricyclic thrombin receptor antagonists
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
CA2668744C (en) 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
WO2008067219A2 (en) 2006-11-29 2008-06-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
EP2137158A4 (en) 2007-02-28 2012-04-18 Methylgene Inc LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS)
EP2155753A1 (en) * 2007-05-09 2010-02-24 Novartis Ag Substituted imidazopyridazines as pi3k lipid kinase inhibitors
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
SG187426A1 (en) 2008-01-04 2013-02-28 Intellikine Llc Certain chemical entities, compositions and methods
EP2346508B1 (en) 2008-09-26 2016-08-24 Intellikine, LLC Heterocyclic kinase inhibitors
WO2010059593A1 (en) 2008-11-18 2010-05-27 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
AU2009322187B2 (en) 2008-12-04 2015-02-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of CNS disorders
WO2010065932A1 (en) 2008-12-05 2010-06-10 Designmedix, Inc. Modified chloroquines with single ring moiety or fused ring moiety
US20110135655A1 (en) 2009-01-13 2011-06-09 PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
JP2012521994A (ja) 2009-03-24 2012-09-20 ギリアード カリストガ エルエルシー 2−プリニル−3−トリル−キナゾリノン誘導体のアトロプ異性体および使用方法
BR112012002331A2 (pt) 2009-08-05 2019-09-24 Versitech Ltd composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
WO2011083387A1 (en) * 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
CN201676365U (zh) 2010-03-29 2010-12-22 山东京卫制药有限公司 带有语音提示的给药吸入装置
CN201692450U (zh) 2010-06-22 2011-01-05 于清 用于药物输送的高效干粉吸入器
US20130157991A1 (en) * 2010-08-31 2013-06-20 Osama Ahmed Aswania Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties and Methods of Administering the Same
ES2704688T3 (es) 2010-09-30 2019-03-19 Chiesi Farm Spa Uso de estearato de magnesio en formulaciones de polvo seco para inhalación
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
CN202154919U (zh) 2011-05-03 2012-03-07 王晓明 一种防交叉感染雾化吸入装置
UA115544C2 (uk) 2012-03-13 2017-11-27 Респіверт Лімітед Спосіб підвищення стабільності до хімічного розкладання фармацевтичної композиції та застосування стабілізуючого агента у фармацевтичній коипозиції

Similar Documents

Publication Publication Date Title
JP2015509972A5 (enExample)
JP2015509973A5 (enExample)
NZ627963A (en) Dry powder pharmaceutical formulations for inhalation of a compound that inhibits pi3 kinase
HRP20210928T1 (hr) Soli ili ko-kristali 3- (3-dimetilamino-1-etil-2-metil-propil)-fenola
AU2020203497B2 (en) Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
JP2018534348A5 (enExample)
JP2018035160A5 (enExample)
JP2012041365A5 (enExample)
JP2013541595A5 (enExample)
JP2014037426A5 (enExample)
JP2017504635A5 (enExample)
JP2014532638A5 (enExample)
BR112012019374A2 (pt) composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo
RU2016123828A (ru) Комбинированная композиция для перорального введения, содержащая эзетимиб и розувастатин
CZ2016276A3 (cs) Pevné formy volné báze ibrutinibu
JP6243265B2 (ja) ロスバスタチン含有医薬製剤
JP2009040767A5 (enExample)
JP2017507980A5 (enExample)
RU2016106336A (ru) Противотуберкулезная композиция, содержащая рифампицин, изониазид, этамбутол и пиразинамид, и способ ее получения
NO20070952L (no) Formuleringer av suberoylanilidhydroksaminsyre og fremgangsmate for fremstilling av slike
JP2011500819A5 (enExample)
JP2020510061A5 (enExample)
JP2020500168A5 (enExample)
JP2013526579A5 (enExample)
JP2018528238A5 (enExample)